Atlanta teenager gets new chance at life after medical emergency
An Atlanta teenager and Clark Atlanta University student is getting a chance to get her life back together after a terrifying ordeal that put her in the hospital.
Channel 2's Linda Stouffer spoke to Onyx Middleton and her mother, Cherise, about the condition that looked like a psychiatric issue, but was really a medical emergency.
It all happened last year while her mother says Onyx was in class.
'She just started crying out of the blue, it became hysterical screaming,' Cherise said.
[DOWNLOAD: Free WSB-TV News app for alerts as news breaks]
That's what took Onyx from the classroom to critical care.
Her mom said it looked like Onyx was having a mental breakdown and was transferred to a mental health facility.
'Yeah, they thought it was schizophrenia,' Cherise said.
It wasn't until medical testing in the intensive care unit at Children's Healthcare of Atlanta that the family got an explanation.
TRENDING STORIES:
Today marks 20 years since deadly Fulton County Courthouse shooting rampage
Atlanta police confirm arrest of man accused of slashing homeless tents
Teen flips attacker during brawl over prom dress in Gwinnett, police say
'Honestly a year ago? I don't remember much at all,' Onyx told Channel 2 Action News.
A doctor at Children's Healthcare of Atlanta was able to diagnose her with an auto-immune condition called anti-NMDA receptor encephalitis.
'It basically shuts down a part of my brain and makes me have seizures,' Onyx said.
Pediatric neurologist Dr. Varun Kannan told Stouffer that it's possible they'll never know exactly what triggered Onyx's immune system to attack her body, but the medical team at Children's Healthcare of Atlanta treated her quickly and carefully with immunotherapy medication.
Kannan said it's easy to miss the diagnosis of anti-NMDA receptor encephalitis because it looks so similar to a mental health crisis.
'I think with early diagnosis and aggressive treatment, as Onyx received, there can be a really happy outcome,' Kannan said. 'There are red flag symptoms, so if you have sudden onset psychosis in a previously healthy teenage young adult, or symptoms like seizures, you really should ask a neurologist 'could this be something else?''
Anti-NMDA receptor encephalitis has only been studied in the past 20 years.
For Onyx, after 118 days in the hospital, she's sharing her journey on social media, hoping the next young adult with strange symptoms finds hope.
Onyx told Channel 2 Action News that she's planning her college comeback now.
'I definitely want to go back and get my degree,' she said.
[SIGN UP: WSB-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
VA secretary calls out California officials after LA anti-ICE riots shutter clinic serving veterans
Veterans Affairs Secretary Doug Collins called out California officials for ignoring the impact the Los Angeles anti-ICE riots have had on displaced veterans after an ambulatory clinic was forced to suddenly shutter its doors earlier this month. "They're not peaceful. We see what they're doing. They're throwing stuff at us. They're taking it out on the police," he said of the protesters on "Fox & Friends," Wednesday. "What Gavin Newsom and… the mayor, don't want to talk about is the impact on the people who are just trying to live their lives… we have a large homeless population of veterans [in Los Angeles]… which we're working on fixing… but we've got a lot who just need that basic care." Exclusive: Va Dept Says La Riots Forced Community Center Closures Impacting More Than 600 Veterans Collins said the local benefits office is also closed, meaning veterans are struggling to receive the help they need in multiple ways. He also said workers have been displaced as a result of the chaos. Read On The Fox News App "Nobody talks about that… the governor out there and the mayor – why don't they actually talk about the real issue, and that's that we can't get services to the people that need it?" The now-closed Los Angeles VA clinic provided cancer care, suicide prevention, pain management, amputation care and traumatic brain injury services. Maxine Waters Taunts Armed Agents After Feds Slam Door On Her During La Riots: 'You Better Shoot Straight' Collins said the VA has transferred as many patients as possible to telehealth services to continue their care, but says there's little substitute for traditional treatment. "I'm tired of this idea that we're trying to help our veterans, help Americans, but yet we're letting the folks in L.A. run wild and graffiti our buildings and do the things that stop us from actually taking care of our veterans," he said. Fox News Digital reached out to the offices of Gov. Gavin Newsom and Mayor Karen Bass for a prior report on this issue. Fox News Digital's Charles Creitz contributed to this article source: VA secretary calls out California officials after LA anti-ICE riots shutter clinic serving veterans
USA Today
3 days ago
- USA Today
'Cruelty over care': Transgender care advocates blast Supreme Court
'Cruelty over care': Transgender care advocates blast Supreme Court Show Caption Hide Caption Supreme Court will hear case about bans on gender-affirming care for minors A case involving a law in Tennessee that restricts puberty blockers and hormone therapy for transgender minors will be heard by the Supreme Court. Scripps News Organizations and advocates for transgender youth blasted the U.S. Supreme Court's decision on June 18 that upheld Tennessee's ban on gender-affirming care for minors. Advocates said the high court's decision was a major blow to transgender rights and medical organizations that have endorsed gender-affirming care for minors. The decision came about five years after the court ruled that transgender, gay and lesbian people are protected by a landmark civil rights law barring sex discrimination in the workplace. In the Tennessee case, the high court said that preventing minors from using puberty blockers and hormone therapy does not violate the equal protection clause of the 14th Amendment. The Tennessee House Republican Caucus cheered the ruling as a "proud day for the Volunteer state and for all those who believe in protecting the innocence and well-being of America's children." The Tennessee Equality Project, an advocacy group that fights anti-LGBTQ legislation, said in a statement that the organization was "profoundly disappointed" by the high court's decision. The decision further erodes the rights of transgender children, their families and doctors, the group said. "Gender-affirming care is proven to save lives," the group's statement said. "Major medical associations, including the American Academy of Pediatrics and the American Medical Association, support gender-affirming medical and psychological care because it saves lives and improves mental well-being." Kimberly Inez McGuire, executive director of Unite for Reproductive & Gender Equity, said the Supreme Court chose "cruelty over care." "This decision upholds a dangerous and deeply unjust law that strips families of their rights, criminalizes love and support and puts the lives of young people at risk," McGuire said in a statement. The decision means transgender adolescents who live in states that restrict gender-affirming care could have difficulty accessing such care, said Lindsey Dawson, associate director for HIV policy and director for LGBTQ health policy at KFF, a health policy nonprofit. Dawson said 25 states have gender-affirming care bans in effect, though only Arizona and New Hampshire ban gender-reassignment surgery. Some transgender youth who live in states restricting care such as puberty blockers or hormone therapy might choose visit states without such bans. However, that option wouldn't be an option for transgender youth and their families who lack the financial means to travel for care. "If you are minor who needs access to this medically necessary care, you simply can't get it if you live in one of these states," Dawson said. More details: Supreme Court to weigh key transgender care case: What's at stake for minors Trump administration targets transgender care The decision comes as President Donald Trump's administration has targeted other aspects of transgender care. After taking office, Trump signed an executive order stating the U.S. would not "fund, sponsor, promote, assist, or support" gender-affirming care. In April, the federal agency that oversees Medicare and Medicaid told states not to use Medicaid funding to pay for gender-affirming care for minors. Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, said the federal agency will stop paying for gender reassignment operations or hormone treatments for those under 18. A 2023 study in the medical journal JAMA Network Open found gender-affirming surgeries were most popular with young adults. More than 25,000 people ages 19 to 30 received these procedures from 2016 through 2019. Fewer than 8% of patients − a total of 3,678 − were 12- to 18-year-olds. Contributing: Maureen Groppe,
Miami Herald
3 days ago
- Miami Herald
MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology
MIAMI, FL / ACCESS Newswire / June 18, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that the first manuscript describing its lead drug candidate Ketamir-2, currently being evaluated in an ongoing Phase 1 clinical trial for neuropathic pain, has been accepted for publication in the peer-reviewed journal Frontiers in Pharmacology. The article, titled "KETAMIR-2, A NEW MOLECULAR ENTITY AND NOVEL KETAMINE ANALOG," authored by Itzchak Angel, Ph.D., MIRA's Chief Scientific Advisor, highlights Ketamir-2's pharmacological differentiation from ketamine and its potential as a next-generation CNS therapeutic. Peer Review Validates Differentiated Pharmacology and Safety Acceptance into Frontiers in Pharmacology provides external scientific validation by independent experts, underscoring the rigor and credibility of MIRA's research. The publication confirms that Ketamir-2 was specifically engineered to overcome limitations associated with ketamine-such as poor oral bioavailability, dissociative side effects, and non-specific receptor binding. Key Highlights from the Publication: Highly Selective, Cleaner Mechanism: Ketamir-2 is a low-affinity NMDA receptor antagonist that selectively targets the NMDA PCP site. Unlike ketamine, Ketamir-2 showed no significant interaction with over 40 other receptors, transporters, or ion channel targets-including dopamine, opioid, serotonin, and monoaminergic systems-highlighting its clean pharmacological profile and reduced off-target Hyperlocomotion, Even at High Doses: In contrast to ketamine, Ketamir-2 did not induce hyperlocomotion in preclinical models-a behavior associated with agitation and schizophrenia-like symptoms-suggesting a favorable neurobehavioral safety Antidepressant and Anxiolytic Activity: In validated behavioral models (Open Field Test, Elevated Plus Maze, Forced Swim Test), Ketamir-2 demonstrated clear anxiolytic and antidepressant-like effects. Ketamine, used as a control, either showed no benefit or limited effect in most Delivery with Efficient Brain Penetration: All studies were conducted via the oral route. Ketamir-2 was shown to cross the blood-brain barrier and is not a substrate for P-glycoprotein, which often limits oral drug delivery to the brain. This may explain Ketamir-2's ability to maintain CNS activity despite its lower NMDA receptor affinity. "We are honored to see our foundational research on Ketamir-2 published in a high-impact scientific journal," said Erez Aminov, CEO of MIRA. "This milestone adds meaningful scientific credibility and supports our confidence in Ketamir-2's differentiated mechanism, favorable safety profile, and broad clinical potential." "This peer-reviewed publication provides clear validation of the differentiated pharmacological profile of Ketamir-2," added Dr. Itzchak Angel, Chief Scientific Advisor. "Its clean pharmacological profile and safety make it a compelling next-generation alternative to ketamine." Clinical and Corporate Updates MIRA also announced that its Phase 1 trial of Ketamir-2 is progressing as planned, with no safety concerns reported to date and dose escalation advancing. The Company expects to initiate a Phase 2a clinical trial in neuropathic pain by year-end 2025, pending regulatory clearance. In addition, the Company is preparing new scientific data submissions and presentations to further support Ketamir-2's clinical development and potential across CNS-related conditions. MIRA also reaffirmed that the acquisition of SKNY Pharmaceuticals, which includes a first-in-class oral CB1/CB2 inverse agonist for obesity and smoking cessation (SKNY-1), is progressing on track. The Company has submitted the required regulatory filings for the merger to the U.S. Securities and Exchange Commission (SEC). The publication will be available upon release at: Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at and MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals
